Literature DB >> 16365082

PYY[3-36] administration decreases the respiratory quotient and reduces adiposity in diet-induced obese mice.

Sean H Adams1, Chunli Lei, Carolyn M Jodka, Svetlana E Nikoulina, Julie A Hoyt, Bronislava Gedulin, Christine M Mack, Eric S Kendall.   

Abstract

In rodents, weight reduction after peptide YY[3-36] (PYY[3-36]) administration may be due largely to decreased food consumption. Effects on other processes affecting energy balance (energy expenditure, fuel partitioning, gut nutrient uptake) remain poorly understood. We examined whether s.c. infusion of 1 mg/(kg x d) PYY[3-36] (for up to 7 d) increased metabolic rate, fat combustion, and/or fecal energy loss in obese mice fed a high-fat diet. PYY[3-36] transiently reduced food intake (e.g., 25-43% lower at d 2 relative to pretreatment baseline) and decreased body weight (e.g., 9-10% reduction at d 2 vs. baseline) in 3 separate studies. Mass-specific metabolic rate in kJ/(kg x h) in PYY[3-36]-treated mice did not differ from controls. The dark cycle respiratory quotient (RQ) was transiently decreased. On d 2, it was 0.747 +/- 0.008 compared with 0.786 +/- 0.004 for controls (P < 0.001); light cycle RQ was reduced throughout the study in PYY[3-36]-treated mice (0.730 +/- 0.006) compared with controls (0.750 +/- 0.009; P < 0.001). Epididymal fat pad weight in PYY[3-36]-treated mice was approximately 50% lower than in controls (P < 0.01). Fat pad lipolysis ex vivo was not stimulated by PYY[3-36]. PYY[3-36] decreased basal gallbladder emptying in nonobese mice. Fecal energy loss was negligible ( approximately 2% of ingested energy) and did not differ between PYY[3-36]-treated mice and controls. Thus, negative energy balance after PYY[3-36] administration in diet-induced obese mice results from reduced food intake with a relative maintenance of mass-specific energy expenditure. Fat loss and reduced RQ highlight the potential for PYY[3-36] to drive increased mobilization of fat stores to help meet energy requirements in this model.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16365082     DOI: 10.1093/jn/136.1.195

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  21 in total

Review 1.  Gut hormones as potential new targets for appetite regulation and the treatment of obesity.

Authors:  Benjamin C T Field; Alison M Wren; Dunstan Cooke; Stephen R Bloom
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 2.  Obesity treatment: novel peripheral targets.

Authors:  Benjamin C T Field; Owais B Chaudhri; Stephen R Bloom
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

3.  NPY receptors as potential targets for anti-obesity drug development.

Authors:  Ernie Yulyaningsih; Lei Zhang; Herbert Herzog; Amanda Sainsbury
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

Review 4.  Appetite responses to high-fat meals or diets of varying fatty acid composition: a comprehensive review.

Authors:  S Kaviani; J A Cooper
Journal:  Eur J Clin Nutr       Date:  2017-01-18       Impact factor: 4.016

Review 5.  Obesity surgery and gut-brain communication.

Authors:  Hans-Rudolf Berthoud; Andrew C Shin; Huiyuan Zheng
Journal:  Physiol Behav       Date:  2011-02-24

6.  Resveratrol suppresses body mass gain in a seasonal non-human primate model of obesity.

Authors:  Alexandre Dal-Pan; Stéphane Blanc; Fabienne Aujard
Journal:  BMC Physiol       Date:  2010-06-22

7.  Differential secretion of satiety hormones with progression of obesity in JCR:LA-corpulent rats.

Authors:  Jill A Parnell; Raylene A Reimer
Journal:  Obesity (Silver Spring)       Date:  2008-01-24       Impact factor: 5.002

8.  Leptin extends the anorectic effects of chronic PYY(3-36) administration in ad libitum-fed rats.

Authors:  Suraj Unniappan; Timothy J Kieffer
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-04-16       Impact factor: 3.619

9.  Sustained weight loss after Roux-en-Y gastric bypass is characterized by down regulation of endocannabinoids and mitochondrial function.

Authors:  Ana Guijarro; Douglas Osei-Hyiaman; Judith Harvey-White; George Kunos; Susumu Suzuki; Sergiy Nadtochiy; Paul S Brookes; Michael M Meguid
Journal:  Ann Surg       Date:  2008-05       Impact factor: 12.969

10.  Acute peripheral GLP-1 receptor agonism or antagonism does not alter energy expenditure in rats after Roux-en-Y gastric bypass.

Authors:  Kathrin Abegg; Marc Schiesser; Thomas A Lutz; Marco Bueter
Journal:  Physiol Behav       Date:  2013-04-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.